Clinical Trial Update: A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating BAY86-6150 for Hemophilia A and Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY86-6150 (BAY86-6150)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A, Hemophilia B | Phase 2, Phase 3 | Status: COMPLETED